- Report
- April 2023
- 120 Pages
Global
From €4509EUR$4,750USD£3,804GBP
- Report
- January 2022
- 115 Pages
Global
From €4509EUR$4,750USD£3,804GBP
- Report
- February 2021
- 108 Pages
Asia Pacific
From €3275EUR$3,450USD£2,763GBP
- Report
- November 2023
- 140 Pages
Global
From €3417EUR$3,599USD£2,882GBP
- Report
- April 2023
- 140 Pages
Global
From €4698EUR$4,949USD£3,963GBP
- Report
- September 2020
- 700 Pages
Global
From €4652EUR$4,900USD£3,924GBP
- Report
- October 2024
- 78 Pages
Global
From €3500EUR$3,949USD£3,056GBP
- Report
- March 2024
- 132 Pages
Global
From €902EUR$950USD£761GBP
- Report
- October 2022
- 188 Pages
Global
From €3389EUR$3,570USD£2,859GBP
Autologous cell therapy is a type of regenerative medicine that uses a patient's own cells to treat a variety of diseases and conditions. It is a form of personalized medicine that is based on the patient's own genetic makeup. Autologous cell therapy is used to treat a variety of conditions, including cancer, autoimmune diseases, and degenerative diseases. Genomics plays an important role in autologous cell therapy, as it allows for the identification of the patient's own cells and the selection of the most appropriate cells for the therapy. Genomics also helps to identify the best treatment strategy for the patient, as well as to monitor the progress of the therapy.
Some companies in the autologous cell therapy market include Celgene, Novartis, and Kite Pharma. Show Less Read more
